![]() |
Name |
Trichoverrol B
|
Molecular Formula | C23H32O7 | |
IUPAC Name* |
[(1S,2R,7R,9R,11R,12S)-2-(hydroxymethyl)-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-11-yl] (2Z,4E,6S,7R)-6,7-dihydroxyocta-2,4-dienoate
|
|
SMILES |
CC1=C[C@@H]2[C@](CC1)([C@]3([C@@H](C[C@H]([C@@]34CO4)O2)OC(=O)/C=C\C=C\[C@@H]([C@@H](C)O)O)C)CO
|
|
InChI |
InChI=1S/C23H32O7/c1-14-8-9-22(12-24)18(10-14)29-19-11-17(21(22,3)23(19)13-28-23)30-20(27)7-5-4-6-16(26)15(2)25/h4-7,10,15-19,24-26H,8-9,11-13H2,1-3H3/b6-4+,7-5-/t15-,16+,17-,18-,19-,21-,22-,23+/m1/s1
|
|
InChIKey |
QFKRKMXPKBHGGO-ACGMSUMJSA-N
|
|
Synonyms |
Trichoverrol B; 76685-83-1; W4NA17W416; [(1S,2R,7R,9R,11R,12S)-2-(hydroxymethyl)-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-11-yl] (2Z,4E,6S,7R)-6,7-dihydroxyocta-2,4-dienoate; UNII-W4NA17W416; Trichothec-9-ene-4,15-diol, 12,13-epoxy-, 4-((2Z,4E,6S,7R)-6,7-dihydroxy-2,4-octadienoate), (4beta)-; Q27896816; TRICHOTHEC-9-ENE-4,15-DIOL, 12,13-EPOXY-, 4-((2Z,4E,6S,7R)-6,7-DIHYDROXY-2,4-OCTADIENOATE), (4.BETA.)-; TRICHOTHEC-9-ENE-4,15-DIOL, 12,13-EPOXY-, 4-(6,7-DIHYDROXY-2,4-OCTADIENOATE), (4.BETA.(2Z,4E,6S,7R))-
|
|
CAS | 76685-83-1 | |
PubChem CID | 6440552 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 420.5 | ALogp: | 0.6 |
HBD: | 3 | HBA: | 7 |
Rotatable Bonds: | 7 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 109.0 | Aromatic Rings: | 4 |
Heavy Atoms: | 30 | QED Weighted: | 0.198 |
Caco-2 Permeability: | -5.152 | MDCK Permeability: | 0.00001760 |
Pgp-inhibitor: | 0.603 | Pgp-substrate: | 0.155 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.519 |
30% Bioavailability (F30%): | 0.428 |
Blood-Brain-Barrier Penetration (BBB): | 0.204 | Plasma Protein Binding (PPB): | 78.03% |
Volume Distribution (VD): | 0.87 | Fu: | 17.03% |
CYP1A2-inhibitor: | 0.035 | CYP1A2-substrate: | 0.194 |
CYP2C19-inhibitor: | 0.349 | CYP2C19-substrate: | 0.506 |
CYP2C9-inhibitor: | 0.246 | CYP2C9-substrate: | 0.041 |
CYP2D6-inhibitor: | 0.009 | CYP2D6-substrate: | 0.058 |
CYP3A4-inhibitor: | 0.557 | CYP3A4-substrate: | 0.316 |
Clearance (CL): | 4.865 | Half-life (T1/2): | 0.826 |
hERG Blockers: | 0.031 | Human Hepatotoxicity (H-HT): | 0.586 |
Drug-inuced Liver Injury (DILI): | 0.36 | AMES Toxicity: | 0.972 |
Rat Oral Acute Toxicity: | 0.384 | Maximum Recommended Daily Dose: | 0.674 |
Skin Sensitization: | 0.81 | Carcinogencity: | 0.366 |
Eye Corrosion: | 0.006 | Eye Irritation: | 0.08 |
Respiratory Toxicity: | 0.132 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003277 | ![]() |
0.495 | D0FG6M | ![]() |
0.254 | ||
ENC005756 | ![]() |
0.449 | D0Y2YP | ![]() |
0.212 | ||
ENC002231 | ![]() |
0.424 | D0Y7IU | ![]() |
0.209 | ||
ENC004001 | ![]() |
0.365 | D04QNO | ![]() |
0.209 | ||
ENC005222 | ![]() |
0.361 | D02JNM | ![]() |
0.206 | ||
ENC001879 | ![]() |
0.351 | D05ZTH | ![]() |
0.203 | ||
ENC006152 | ![]() |
0.330 | D08PIQ | ![]() |
0.202 | ||
ENC004775 | ![]() |
0.324 | D07DVK | ![]() |
0.198 | ||
ENC004660 | ![]() |
0.310 | D0CW1P | ![]() |
0.198 | ||
ENC003173 | ![]() |
0.308 | D0IT2G | ![]() |
0.198 |